Free Trial

ARS Pharmaceuticals (NASDAQ:SPRY) Shares Up 4.9% - Here's Why

ARS Pharmaceuticals logo with Medical background

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Get Free Report)'s share price traded up 4.9% during trading on Friday . The stock traded as high as $14.99 and last traded at $15.10. 296,156 shares were traded during trading, a decline of 77% from the average session volume of 1,283,612 shares. The stock had previously closed at $14.40.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the stock. Scotiabank started coverage on shares of ARS Pharmaceuticals in a report on Friday, March 7th. They issued a "sector outperform" rating and a $30.00 price target on the stock. William Blair reissued an "outperform" rating on shares of ARS Pharmaceuticals in a research note on Monday, March 3rd. Finally, Wall Street Zen lowered shares of ARS Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Thursday, May 22nd. One investment analyst has rated the stock with a sell rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $31.00.

Get Our Latest Research Report on ARS Pharmaceuticals

ARS Pharmaceuticals Stock Down 1.5%

The firm's 50-day moving average is $14.20 and its 200-day moving average is $12.83. The company has a market capitalization of $1.49 billion, a PE ratio of -29.73 and a beta of 0.84.

ARS Pharmaceuticals (NASDAQ:SPRY - Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($0.35) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.35). The business had revenue of $7.97 million for the quarter, compared to analysts' expectations of $7.48 million. As a group, equities research analysts predict that ARS Pharmaceuticals, Inc. will post -0.55 EPS for the current year.

Insider Buying and Selling at ARS Pharmaceuticals

In related news, Director Brent L. Saunders sold 120,000 shares of ARS Pharmaceuticals stock in a transaction that occurred on Tuesday, May 20th. The stock was sold at an average price of $14.25, for a total transaction of $1,710,000.00. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Laura Shawver sold 50,002 shares of the firm's stock in a transaction on Monday, April 7th. The shares were sold at an average price of $12.30, for a total transaction of $615,024.60. Following the transaction, the director now directly owns 210,346 shares of the company's stock, valued at $2,587,255.80. The trade was a 19.21% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 332,971 shares of company stock valued at $4,621,888. Corporate insiders own 33.50% of the company's stock.

Institutional Trading of ARS Pharmaceuticals

Several hedge funds have recently bought and sold shares of the stock. Bernard Wealth Management Corp. purchased a new stake in shares of ARS Pharmaceuticals during the 4th quarter valued at about $27,000. ANTIPODES PARTNERS Ltd purchased a new stake in shares of ARS Pharmaceuticals during the 1st quarter valued at about $37,000. GAMMA Investing LLC raised its position in shares of ARS Pharmaceuticals by 4,319.7% during the 1st quarter. GAMMA Investing LLC now owns 3,359 shares of the company's stock valued at $420,000 after buying an additional 3,283 shares in the last quarter. PNC Financial Services Group Inc. raised its position in shares of ARS Pharmaceuticals by 78,100.0% during the 1st quarter. PNC Financial Services Group Inc. now owns 3,910 shares of the company's stock valued at $49,000 after buying an additional 3,905 shares in the last quarter. Finally, KLP Kapitalforvaltning AS purchased a new stake in shares of ARS Pharmaceuticals during the 4th quarter valued at about $73,000. Hedge funds and other institutional investors own 68.16% of the company's stock.

ARS Pharmaceuticals Company Profile

(Get Free Report)

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.

Further Reading

Should You Invest $1,000 in ARS Pharmaceuticals Right Now?

Before you consider ARS Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ARS Pharmaceuticals wasn't on the list.

While ARS Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Cheap Growth Stocks Set to Explode This Summer
The Next NVIDIA? Quantum Computing Stocks Set for Explosive Growth
5 Stocks to BUY NOW in July 2025

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines